Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))
Publication date
2024-03
Authors
van Dijk, Myrthe J
de Wilde, Jonathan R A
Bartels, M
Kuo, Kevin H.M.
Glenthøj, Andreas
Rab, Minke A E
van Beers, Eduard
van Wijk, Richard
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
Abstract
The authors regret that in the published article, a part of Table 2 titled ‘Main clinical study results of subjects treated with PK activators in hereditary hemolytic anemia’ was missing. A correction has therefore been made to Table 2 with the addition of the last three columns and some abbreviations in the legend. The original article has been updated. The authors would like to apologise for any inconvenience caused.
Keywords
Hematology, Oncology, Published Erratum
Citation
van Dijk, M J, de Wilde, J R A, Bartels, M, Kuo, K H M, Glenthøj, A, Rab, M A E, van Beers, E J & van Wijk, R 2024, 'Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias : Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))', Blood Reviews, vol. 64, 101160. https://doi.org/10.1016/j.blre.2023.101160